Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
Suppression failure of cortisol secretion by dexamethasone may occur in glucagon-like peptide-1 receptor agonist-treated patients with diabetic autonomic neuropathy
It goes undertreated not because it is complex, but because it goes untested
Never stop taking Mounjaro without consulting your healthcare provider , as abrupt discontinuation may lead to worsening blood glucose control
How Serena Williams admission of using a GLP-1 drug could impact the stigma of obesity Serena Williams GLP-1 disclosure may shift obesity conversations, though treatment requires a holistic approach, Northeastern experts say
Es altamente selectiva: muchas molculas que circulan en sangre no pueden entrar al cerebro en cantidades biolgicamente relevantes
